Brain alanyl aminopeptidase degraded leu-enkephalin 230× faster than dynorphin(1-17) — larger opioid peptides are naturally protected from this enzyme.
230× faster for short peptidesEnkephalin (5 residues) vs dynorphin (17 residues) degradation rate
What the researchers found
Brain alanyl aminopeptidase's efficiency drops dramatically with opioid peptide chain length. Dynorphin(1-17) acts as a competitive inhibitor rather than a substrate.
Why it matters
This explains why different opioid peptides last different amounts of time in the brain. Longer peptides like dynorphin resist breakdown, which affects how long their signals last.
How the study worked
Enzyme was purified to homogeneity from human cerebral cortex. Kinetic analysis measured cleavage rates for a series of leu-enkephalin-related peptides of increasing length.
What this study cannot tell us
This was an in-vitro study with purified enzyme. In living brain tissue, multiple enzymes act simultaneously, so the actual breakdown pattern may differ.
How to read the evidence
Preliminary in-vitro study with purified human brain enzyme — clean kinetic data.
When this study was published
Published in 1989 — established chain length as a determinant of peptide stability.
The bigger picture
Peptide chain length is a natural defense against enzymatic degradation. This principle is directly applicable to designing longer-lasting therapeutic peptides.
Questions still open
- Could extending therapeutic peptides improve their half-life?
- Do longer endogenous opioid peptides have longer signaling duration?
Common questions
Why do small peptides break down faster?
How does this help drug design?
Read the original research
Specificity of action of human brain alanyl aminopeptidase on Leu-enkephalin and dynorphin-related peptides.
Neuropeptides, 13(4), 259-62
Citation
Gibson, A M; McDermott, J R; Lauffart, B; Mantle, D. (1989). Specificity of action of human brain alanyl aminopeptidase on Leu-enkephalin and dynorphin-related peptides.. Neuropeptides, 13(4), 259-62.